VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA s
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: Athanasios Dimopoulos Efstathios Kastritis Ofer Shpilberg William Deraedt Maria Teresa Petrucci Michel Delforge María Victoria Mateos Helgi van de Velde Rik Schots Paul G. Richardson Nuriet K Khuageva Jesús San Miguel Andrew Cakana Tamás Masszi |
| Publication date | October 26, 2009 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |